Drug Type T-lymphocyte cell therapy |
Synonyms- |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Neoplasms | Phase 2 | US | 01 Jun 2008 | |
Melanoma, Cutaneous Malignant | Phase 2 | US | 01 Jun 2008 | |
Neoplasm Metastasis | Phase 2 | US | 01 Jun 2008 |
Phase 2 | 3 | autologous dendritic cell-adenovirus p53 vaccine+fludarabine phosphate+cyclophosphamide+Filgrastim+anti-p53 T-cell receptor-transduced peripheral blood lymphocytes+aldesleukin (Anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC) | ffrsxswjcs(ezwelmnwjp) = hieatyhuqs hxbkpejypa (dahdahhfbo, dqgxvocqyq - enlnoqaghy) View more | - | 14 Aug 2012 | ||
autologous dendritic cell-adenovirus p53 vaccine+fludarabine phosphate+cyclophosphamide+Filgrastim+anti-p53 T-cell receptor-transduced peripheral blood lymphocytes+aldesleukin (Anti-p53 TCR PBL + DC + IL-2: Other Histology) | ffrsxswjcs(ezwelmnwjp) = hocrkjixkj hxbkpejypa (dahdahhfbo, rjavleiqye - tcqkxprtrc) View more |